EcoDrugPlus

Kit Proto-Oncogene Receptor Tyrosine Kinase

Ensembl ID : ENSPEMG00000011261
Gene Symbol: KIT
1 Cross references
265 Possible Orthologues:

Kirsten Rat Sarcoma Viral Oncogene Homolog

Ensembl ID : ENSPEMG00000025855
Gene Symbol: KRAS
1 Cross references
201 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSPEMG00000021545
Gene Symbol: LYN
3 Cross references
202 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSPEMG00000017866
Gene Symbol: MALT1
3 Cross references
195 Possible Orthologues:

Map Kinase-Activated Protein Kinase 2

Ensembl ID : ENSPEMG00000010353
Gene Symbol: MAPKAPK2
1 Cross references
233 Possible Orthologues:

Map Kinase-Activated Protein Kinase 5

Ensembl ID : ENSPEMG00000018267
Gene Symbol: MAPKAPK5
1 Cross references
179 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2

Ensembl ID : ENSPEMG00000023115
Gene Symbol: MKNK2
3 Cross references
220 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSPEMG00000021204
Gene Symbol: MET
3 Cross references
211 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSPEMG00000014255
Gene Symbol: MLST8
3 Cross references
201 Possible Orthologues:

Nad(P)h Dehydrogenase, Quinone 1

Ensembl ID : ENSPEMG00000015874
Gene Symbol: NQO1
1 Cross references
195 Possible Orthologues:

Nadph Oxidase 4

Ensembl ID : ENSPEMG00000021901
Gene Symbol: NOX4
3 Cross references
151 Possible Orthologues:

Npc1 Like Intracellular Cholesterol Transporter 1

Ensembl ID : ENSPEMG00000014976
Gene Symbol: NPC1L1
3 Cross references
189 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).